Article Text

Download PDFPDF

548 Evolution of myeloid-mediated mechanisms of immunotherapy resistance at single-cell resolution with human prostate cancer progression
  1. Aram Lyu1,2,
  2. Zenghua Fan3,
  3. Diamond Luong1,
  4. Ali Setayesh1,
  5. Alec Starzinski1,
  6. Eliezer Van Allen3,4 and
  7. Lawrence Fong1,2
  1. 1University of California San Francisco, San Francisco, CA, USA
  2. 2Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
  3. 3Dana-Farber Cancer Institute, Boston, MA, USA
  4. 4Broad Institute of Harvard and MIT, Cambridge, MA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Patients with metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs).1 2 Although prostate cancer is highly populated by multiple immunosuppressive myeloid cells especially after androgen deprivation therapy (ADT),3 efforts to therapeutically target myeloid cells broadly have thus far failed clinically, potentially due to myeloid cell heterogeneity and complexity.4 5 Understanding the specific myeloid populations relevant in prostate cancer and the molecular mechanisms mediating immunosuppression is needed to improve the efficacy of immunotherapy in this disease.

Methods We performed multi-omic single-cell RNA sequencing (scRNA-seq) on biopsies from prostate cancer patients with either ADT-naïve localized prostate cancer, metastatic hormone-sensitive prostate cancer on ADT, or mCRPC progressing on ADT. We also performed scRNA-seq on immune and non-immune cells isolated from a syngeneic mouse model of CRPC. Functional significance of specific myeloid populations was assessed with immune assays in vitro and tumor efficacy in vivo with this syngeneic model.

Results We identified a specific population of tumor-associated macrophages expressing elevated SPP1 transcripts (SPP1 hi-TAMs) significantly enriched in mCRPC relative to earlier states of prostate cancer. This myeloid population expresses elevated levels of immunosuppressive molecular programs.6–8 Notably, CSF1R transcript levels were drastically diminished in SPP1 hi-TAMs relative to other macrophages, implicating this population as a potential mechanism underlying the clinical ineffectiveness of CSF1R blockade. We then utilized a syngeneic mouse model of CRPC to investigate the specific mechanisms by which SPP1 hi-TAMs mediate resistance to ICIs. Using scRNA-seq, we identified an analogous macrophage state and demonstrated their ability to suppress T-cell proliferation and activation in vitro. Administration of an anti-CSF1R antibody failed to ablate Spp1 hi-TAMs in CRPC, pointing to their immunosuppressive signals as potential immunotherapeutic targets. Adoptive transfer of Spp1 hi-TAMs into tumors promoted resistance to ICIs and worsened survival in vivo. Pathway analyses revealed enrichment of gene signatures associated with the adenosine pathway in SPP1 hi-TAMs both in patients and in mice.9 10 Analyses of The Cancer Genome Atlas (TCGA) database from prostate cancer patients as well as our own patient scRNA-seq dataset indicated that enrichment of the adenosine pathway correlates with SPP1 hi-TAM abundance and CD8+ T-cell exhaustion in tumors. Finally, pharmacologic inhibition of A2AR abrogated Spp1 hi-TAM-mediated immunosuppression on activated T cells in vitro.

Conclusions Our studies demonstrate that as prostate cancer progresses, the abundance of SPP1 hi-TAMs increases. Furthermore, this myeloid population can mediate resistance to ICIs in mCRPC by activating adenosine signaling, supporting the relevance of therapeutically targeting of this pathway in this disease.


  1. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol 2016;35:40–7.

  2. Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 2022;28:144–53.

  3. Fares CM, Allen EMV, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book. 2019;147–64.

  4. Autio KA, Klebanoff CA, Schaer D, Kauh JS, Slovin SF, Blinder VS, et al. Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC). J Clin Oncol. 2019;37:2548–2548.

  5. Hamid M, Heilbrun LK, Maier J, Devisetty K, Connolly I, Kaufman I, et al. A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer. Adv Radiat Oncol. 2021;6:100679.

  6. Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792–809.e23.

  7. Maire CL, Mohme M, Bockmayr M, Fita KD, Riecken K, Börnigen D, et al. Glioma escape signature and clonal development under immune pressure. J Clin Invest. 2020;130:5257–71.

  8. Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021;39:649–661.e5.

  9. Sidders B, Zhang P, Goodwin K, O’Connor G, Russell DL, Borodovsky A, et al. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. Clin Cancer Res. 2020;26:2176–87.

  10. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020;10:40–53.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.